Why don't we initiate more large simple randomized controlled trials?

CMAJ. Canadian Medical Association Journal

Volumn 169, Issue 11, 2003, Pages 1170-1171

  Wright, James M ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB;

ARTHRITIS; CANADA; DRUG COST; DRUG EFFECT; DRUG SAFETY; HUMAN; NOTE; PEPTIC ULCER; PRESCRIPTION; QUESTIONNAIRE; RANDOMIZATION; STANDARDIZATION;

EID: 0344082820     PISSN: 08203946     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (11)

1. Laupacis A, Paterson JM, Mamdani M, Rostom A, Anderson GM. Gaps in the evaluation and monitoring of new pharmaceuticals: proposal for a different approach. CMAJ 2003;169:1167-70.
2. Mamdani M, Rochon P, Laupacis A, Anderson G. Initial patterns of use of coxibs by elderly patients in Ontario: findings and implications. CMAJ 2002;167:1125-6.
3. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al, for the VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000;343:1520-8.
4. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al. Gastrointestinal toxicity with celecoxib versus nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: a randomized controlled trial. JAMA 2000;284:1247-55.
5. Jüni P, Rutjes AWS, Dieppe PA. Are selective COX-2 inhibitors superior to traditional nonsteroidal anti-inflammatory drugs? Adequate analysis of the CLASS trial indicates that this may not be the case [editorial]. Br Med J 2002;324:1287-8.
6. Wright JM. The double-edged sword of COX-2 selective NSAIDs. CMAJ 2002;167:1131-7.
7. Rapid Responses to: Jüni P, Rutjes AWS, Dieppe PA. Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs? Adequate analysis of the CLASS trial indicates that this may not be the case [editorial]. BMJ 2002;324:1287-8. Available: www.bmj.com/cgi/eletters/324 /7349/1287. (Accessed 2003 Jul 16).
8. Mamdani M, Rochon PA, Juurlink DN, Kopp A, Anderson GM, Naglie G, et al. Selective COX-2 inhibitors and nonselective NSAIDs: upper gastrointestinal hemorrhage in an elderly cohort. BMJ 2002;325:624-7.
9. Yusuf S, Collins S, Peto R. Why do we need some large, simple randomized trials? Stat Med 1984;3:409-22.
10. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-97.
11. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33.